KDS-1000

N/A

Report date: 2022/09/06 18:04:05

Base Information

Drug NameKDS-1000

Drug Alias NameKDS-1000

ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy

Mechanisms of ActionImmunologic cytotoxicityNatural killer cell replacements

TargetsUpdating

Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusDiscontinued (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesKiadis Pharma

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesKiadis Pharma

Active IndicationsN/A

Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeN/A